Dow Surges Over 100 Points; Dollar Tree Earnings Miss Expectations
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 13 2024
0mins
Should l Buy SKIN?
Source: Benzinga
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy SKIN?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on SKIN
Wall Street analysts forecast SKIN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for SKIN is 2.13 USD with a low forecast of 1.50 USD and a high forecast of 3.50 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
5 Analyst Rating
1 Buy
4 Hold
0 Sell
Hold
Current: 1.290
Low
1.50
Averages
2.13
High
3.50
Current: 1.290
Low
1.50
Averages
2.13
High
3.50
About SKIN
The Beauty Health Company is a medical technology meets beauty company that delivers skin-health experiences. The Company and its subsidiaries design, develop, manufacture, market, and sell esthetic technologies and products. It specializes in skin health for all ages, genders, skin tones, and skin types. Its brands include Hydrafacial, SkinStylus, and Keravive. Hydrafacial created the category of hydradermabrasion with its patented delivery system that cleanses, extracts, and hydrates the skin with proprietary solutions and serums. SkinStylus specializes in nanoneedling and microneedling, where its products are designed to provide either a non-invasive (nanoneedling) or minimally invasive (microneedling) skin treatment to individuals. Keravive specializes in scalp health with its products that are designed to support the hair’s natural growth by cleansing, exfoliating, and hydrating the scalp and hair follicles.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Beauty Health Company Under Investigation for Restructuring Charges, Sales Guidance Revised to $385-$400 Million
- Declining Financial Performance: Beauty Health Company reported lower-than-expected U.S. revenue in its Q3 2023 results, incurring $63.1 million in restructuring charges related to early-generation Syndeo device upgrades, indicating significant financial strain.
- Sales Guidance Revision: The company has revised its fiscal year 2023 net sales guidance to a range of $385 to $400 million, with adjusted EBITDA margin guidance lowered to 5% to 6%, reflecting uncertainty in future profitability.
- Executive Changes: CEO Stanleick will depart from his roles as President and CEO and relinquish his board seat, which may impact the company's strategic direction and market confidence.
- Legal Litigation Risks: The company and certain executives are facing a securities class action lawsuit for failing to disclose material information, with KSF investigating potential breaches of fiduciary duties, which could negatively affect the company's reputation and stock price.
See More
Skinesa® Achieves No. 2 on 2025 Gator100 with 665% CAGR
- Rapid Growth: Skinesa® achieved a remarkable 665% CAGR over the past three years, earning the No. 2 spot on the University of Florida's Gator100 list, which underscores its leadership and commitment to scientific excellence in the probiotic skincare industry.
- Market Expansion: This year, the company launched chewable skin probiotics for kids, which not only diversifies its product line but also enhances its competitive edge and market share in the skincare sector.
- Strengthened Partnerships: Skinesa® is reinforcing its collaborations with doctors and healthcare professionals to solidify its research position in the skincare industry, which will help enhance brand credibility and customer trust.
- Leadership Remarks: CEO Ryan Walters expressed that earning the No. 2 spot on the Gator100 is a tremendous honor, reflecting the company's values in innovation, leadership, and problem-solving, further motivating the team to pursue purposeful and integrity-driven growth.
See More
Beauty Health Releases 2025 Skintuition Report, 75% Consumers Prioritize Skin Quality
- Consumer Trend Shift: The 2025 report reveals that 75% of consumers now prioritize treatments that enhance overall skin quality over volume-enhancing procedures, indicating a significant shift towards skin regeneration in the market.
- New Product Launch: In June 2025, Hydrafacial introduced the HydraFillic with Pep9™ Booster, a clinically proven booster that visibly improves fine lines and wrinkles, deeply hydrates, and strengthens the skin barrier, addressing the growing consumer demand for skin regeneration.
- Increased Treatment Frequency: Hydrafacial consumers receive an average of 3.6 treatments per year, demonstrating the brand's success in driving customer return visits and loyalty, thereby solidifying its market position in the aesthetics industry.
- Clear Market Positioning: The report highlights a rising consumer demand for “notox” and “skinimalism” treatments, and Hydrafacial is aligning with this trend by offering scientifically-backed, safe treatment options that promote a shift towards more natural beauty standards in the industry.
See More
Halper Sadeh Investigates Beauty Health (SKIN) for Potential Fiduciary Breaches
- Shareholder Rights Investigation: Halper Sadeh LLC is investigating whether certain officers and directors of The Beauty Health Company (NASDAQ:SKIN) breached their fiduciary duties, potentially impacting corporate governance.
- Legal Relief Options: Long-term shareholders of Beauty Health may seek corporate governance reforms, fund returns, or court-approved financial awards, aimed at enhancing the company's transparency and accountability.
- Importance of Shareholder Participation: Shareholder involvement can improve company policies and oversight mechanisms, thereby enhancing shareholder value, highlighting the necessity and urgency of effective corporate governance.
- Legal Fee Arrangement: Halper Sadeh LLC will handle the case on a contingency fee basis, meaning shareholders will not incur out-of-pocket legal fees, reducing the financial burden of participation.
See More
After-Hours Surge in GMED, TNDM, ICUI, ORGO, SKIN, TXG Fueled by Q3 Results
Globus Medical Earnings Surge: Globus Medical's stock rose 24.37% after reporting a Q3 net income of $119 million and raising its 2025 revenue outlook to $2.86-$2.90 billion, with non-GAAP EPS guidance increased to $3.75-$3.85.
Tandem Diabetes Care Recovery: Tandem Diabetes Care's stock rebounded 20.03% after narrowing its Q3 net loss to $21.2 million and reaffirming its 2025 sales guidance of approximately $1 billion.
Organogenesis Holdings Growth: Organogenesis Holdings saw a 19.28% increase in stock price following a Q3 net income of $21.6 million and an updated 2025 revenue forecast of $500-$525 million.
ICU Medical and 10x Genomics Updates: ICU Medical's stock rose 14.14% after narrowing its Q3 net loss, while 10x Genomics advanced 8.92% despite a Q3 net loss, with both companies revising their 2025 guidance.
See More
TD Cowen Keeps Hold Rating on Beauty Health and Increases Price Target to $2.5
Real-time Intelligence: Benzinga Pro offers the fastest news alerts to help traders stay informed and make winning trades in the stock market.
Exclusive Community: Joining Benzinga Pro connects users with over 10,000 serious traders and provides access to exclusive stories and insights from Benzinga reporters.
See More
Beauty Health Company Under Investigation for Restructuring Charges, Sales Guidance Revised to $385-$400 Million
- Declining Financial Performance: Beauty Health Company reported lower-than-expected U.S. revenue in its Q3 2023 results, incurring $63.1 million in restructuring charges related to early-generation Syndeo device upgrades, indicating significant financial strain.
- Sales Guidance Revision: The company has revised its fiscal year 2023 net sales guidance to a range of $385 to $400 million, with adjusted EBITDA margin guidance lowered to 5% to 6%, reflecting uncertainty in future profitability.
- Executive Changes: CEO Stanleick will depart from his roles as President and CEO and relinquish his board seat, which may impact the company's strategic direction and market confidence.
- Legal Litigation Risks: The company and certain executives are facing a securities class action lawsuit for failing to disclose material information, with KSF investigating potential breaches of fiduciary duties, which could negatively affect the company's reputation and stock price.
See More
Skinesa® Achieves No. 2 on 2025 Gator100 with 665% CAGR
- Rapid Growth: Skinesa® achieved a remarkable 665% CAGR over the past three years, earning the No. 2 spot on the University of Florida's Gator100 list, which underscores its leadership and commitment to scientific excellence in the probiotic skincare industry.
- Market Expansion: This year, the company launched chewable skin probiotics for kids, which not only diversifies its product line but also enhances its competitive edge and market share in the skincare sector.
- Strengthened Partnerships: Skinesa® is reinforcing its collaborations with doctors and healthcare professionals to solidify its research position in the skincare industry, which will help enhance brand credibility and customer trust.
- Leadership Remarks: CEO Ryan Walters expressed that earning the No. 2 spot on the Gator100 is a tremendous honor, reflecting the company's values in innovation, leadership, and problem-solving, further motivating the team to pursue purposeful and integrity-driven growth.
See More
Beauty Health Releases 2025 Skintuition Report, 75% Consumers Prioritize Skin Quality
- Consumer Trend Shift: The 2025 report reveals that 75% of consumers now prioritize treatments that enhance overall skin quality over volume-enhancing procedures, indicating a significant shift towards skin regeneration in the market.
- New Product Launch: In June 2025, Hydrafacial introduced the HydraFillic with Pep9™ Booster, a clinically proven booster that visibly improves fine lines and wrinkles, deeply hydrates, and strengthens the skin barrier, addressing the growing consumer demand for skin regeneration.
- Increased Treatment Frequency: Hydrafacial consumers receive an average of 3.6 treatments per year, demonstrating the brand's success in driving customer return visits and loyalty, thereby solidifying its market position in the aesthetics industry.
- Clear Market Positioning: The report highlights a rising consumer demand for “notox” and “skinimalism” treatments, and Hydrafacial is aligning with this trend by offering scientifically-backed, safe treatment options that promote a shift towards more natural beauty standards in the industry.
See More
Halper Sadeh Investigates Beauty Health (SKIN) for Potential Fiduciary Breaches
- Shareholder Rights Investigation: Halper Sadeh LLC is investigating whether certain officers and directors of The Beauty Health Company (NASDAQ:SKIN) breached their fiduciary duties, potentially impacting corporate governance.
- Legal Relief Options: Long-term shareholders of Beauty Health may seek corporate governance reforms, fund returns, or court-approved financial awards, aimed at enhancing the company's transparency and accountability.
- Importance of Shareholder Participation: Shareholder involvement can improve company policies and oversight mechanisms, thereby enhancing shareholder value, highlighting the necessity and urgency of effective corporate governance.
- Legal Fee Arrangement: Halper Sadeh LLC will handle the case on a contingency fee basis, meaning shareholders will not incur out-of-pocket legal fees, reducing the financial burden of participation.
See More
After-Hours Surge in GMED, TNDM, ICUI, ORGO, SKIN, TXG Fueled by Q3 Results
Globus Medical Earnings Surge: Globus Medical's stock rose 24.37% after reporting a Q3 net income of $119 million and raising its 2025 revenue outlook to $2.86-$2.90 billion, with non-GAAP EPS guidance increased to $3.75-$3.85.
Tandem Diabetes Care Recovery: Tandem Diabetes Care's stock rebounded 20.03% after narrowing its Q3 net loss to $21.2 million and reaffirming its 2025 sales guidance of approximately $1 billion.
Organogenesis Holdings Growth: Organogenesis Holdings saw a 19.28% increase in stock price following a Q3 net income of $21.6 million and an updated 2025 revenue forecast of $500-$525 million.
ICU Medical and 10x Genomics Updates: ICU Medical's stock rose 14.14% after narrowing its Q3 net loss, while 10x Genomics advanced 8.92% despite a Q3 net loss, with both companies revising their 2025 guidance.
See More
TD Cowen Keeps Hold Rating on Beauty Health and Increases Price Target to $2.5
Real-time Intelligence: Benzinga Pro offers the fastest news alerts to help traders stay informed and make winning trades in the stock market.
Exclusive Community: Joining Benzinga Pro connects users with over 10,000 serious traders and provides access to exclusive stories and insights from Benzinga reporters.
See More
